BioCentury | Oct 17, 2019
Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

...“Going Big in Europe” ). The CDK7 program is not Syros’ most advanced. The company’s SY-1425...
BioCentury | Dec 14, 2018
Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

...cohort of eight evaluable newly diagnosed, biomarker-positive acute myelogenous leukemia (AML) patients showing that tamibarotene (SY-1425...
...APL). Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd., Tokyo, Japan Product: Amnolake tamibarotene (SY-1425...
...safety Status: Additional Phase II data Milestone: NA Brian Moy Amnolake, tamibarotene (SY-1425, am-80, INNO-507, TM-411, TOS-80T, Z-208) American...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

...neurotoxicity among the 91 patients in all dosing groups Syros Pharmaceuticals Inc. (NASDAQ:SYRS) -27% $8.99 SY-1425...
BioCentury | Dec 15, 2017
Clinical News

Syros discontinues single agent tamibarotene

...Syros Pharmaceuticals Inc. (NASDAQ:SYRS) said only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy...
...tamibarotene plus Vidaza in newly diagnosed AML patients who are ineligible for standard chemotherapy and tamibarotene...
...Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd., Tokyo, Japan Product: Amnolake tamibarotene (SY-1425) (formerly AM-80...
BioCentury | Dec 11, 2017
Clinical News

Syros falls on Phase II AML, MDS data

...to $8.45 on Monday after reporting that only one of 48 evaluable patients receiving tamibarotene (SY-1425...
...tamibarotene plus Vidaza in newly diagnosed AML patients who are ineligible for standard chemotherapy and tamibarotene...
...cancer. Tamibarotene is approved in Japan as Amnolake to treat relapsed/refractory acute promyelocytic leukemia (APL). Allison Johnson azacitidine daratumumab Darzalex tamibarotene Vidaza American...
BioCentury | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

...ACS) 2017 Clinical Congress. Syros has two clinical programs that both indirectly target enhancers. Amnolake tamibarotene...
...which drives expression of differentiation factors in cancer cells by binding to super enhancers. Amnolake...
...and MDS through a target-agnostic super enhancer screen. Based on the results, Syros is testing Amnolake...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...compound Epigenetic target Lead indication Status Amount raised ($M) Investors Syros Pharmaceuticals Inc. (NASDAQ:SYRS) Cancer SY-1425...
BioCentury | Apr 21, 2017
Financial News

Syros, SteadyMed complete private placements

...of $15.54. Syros lost $0.64 to $14.90 on Friday. The company's lead candidate tamibarotene ( SY-1425...
...agonist in North America and Europe to treat cancer. Tamibarotene is approved in Japan as Amnolake...
...year, SteadyMed plans to launch the prostacyclin analog treprostinil delivered via its subcutaneous PatchPump technology. Chris Lieu Amnolake tamibarotene Trevyent SteadyMed...
BioCentury | Apr 18, 2017
Distillery Therapeutics

Neurology

...normal mice. In the mouse model, the synthetic retinoic acid receptor α (RARA) agonist Amnolake tamibarotene...
...GNI Group Ltd. , Nippon Shinyaku Co. Ltd. , and Syros Pharmaceuticals Inc. market Amnolake...
BioCentury | Oct 3, 2016
Clinical News

Tamibarotene: Phase II started

...Syros began an open-label, U.S. Phase II trial evaluating 3 mg/m 2 oral tamibarotene twice daily...
...associated with the RARA pathway. Syros has exclusive rights from TMRC to develop and commercialize tamibarotene...
...Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd. , Tokyo, Japan Product: Tamibarotene (SY-1425) (formerly AM-80...
Items per page:
1 - 10 of 39